Literature DB >> 10886574

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

P Muntner1, J Coresh, J C Smith, J Eckfeldt, M J Klag.   

Abstract

BACKGROUND: Animal and in vitro data suggest that dyslipidemia plays an important role in the initiation and progression of chronic renal disease, but few prospective studies have been conducted in humans.
METHODS: We studied the relationship of plasma lipids to a rise in serum creatinine of 0.4 mg/dL or greater in 12,728 Atherosclerosis Risk in Communities (ARIC) participants with baseline serum creatinine that was less than 2.0 mg/dL in men and less than 1.8 mg/dL in women.
RESULTS: During a mean follow-up of 2.9 years, 191 persons had a rise in creatinine of 0.4 mg/dL or greater, yielding an incidence rate of 5.1 per 1000 person years. Individuals with higher triglycerides and lower high-density lipoprotein (HDL) and HDL-2 cholesterol at baseline were at increased risk for a rise in creatinine after adjustment for race, gender, baseline age, diabetes, serum creatinine, systolic blood pressure, and antihypertensive medication use (all P trends </=0.02). The adjusted relative risk for the highest versus lowest quartile of triglycerides was 1.65 (95% CI, 1.1, 2.5, P = 0.01) and for HDL was 0.47 (95% CI, 0.3, 0.8, P = 0.003). These associations were significant in participants with normal creatinine (defined as <1.4 mg/dL for men and <1.2 mg/dL for women), with diabetes, and without diabetes. The effect of high triglycerides was independent of plasma glucose, but was weaker and less consistent after further adjustment for fasting insulin in nondiabetics.
CONCLUSIONS: High triglycerides and low HDL cholesterol, but not low-density lipoprotein cholesterol, predict an increased risk of renal dysfunction. The treatment of these lipid abnormalities may decrease the incidence of early renal disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886574     DOI: 10.1046/j.1523-1755.2000.00165.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  173 in total

Review 1.  Management of diabetic nephropathy.

Authors:  L Foggensteiner; S Mulroy; J Firth
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

2.  Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

Authors:  Oemer-Necmi Goek; Anna Köttgen; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Nephrol Dial Transplant       Date:  2012-01-28       Impact factor: 5.992

3.  The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic.

Authors:  Joseph B Davies; Martin A Crook; Anthony S Wierzbicki; David J Goldsmith
Journal:  Int Urol Nephrol       Date:  2010-08-13       Impact factor: 2.370

Review 4.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

5.  End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.

Authors:  X L Yang; W Y So; A P S Kong; P Clarke; C S Ho; C W K Lam; M H L Ng; R R Lyu; D D Yin; C C Chow; C S Cockram; P C Y Tong; J C N Chan
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

6.  A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.

Authors:  Md Abdul Hye Khan; Lauren Kolb; Melissa Skibba; Markus Hartmann; René Blöcher; Ewgenij Proschak; John D Imig
Journal:  Diabetologia       Date:  2018-07-21       Impact factor: 10.122

7.  Variability in Total Cholesterol Is Associated With the Risk of End-Stage Renal Disease: A Nationwide Population-Based Study.

Authors:  Mee Kyoung Kim; Kyungdo Han; Eun Sil Koh; Hun-Sung Kim; Hyuk-Sang Kwon; Yong-Moon Park; Kun-Ho Yoon; Seung-Hwan Lee
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-31       Impact factor: 8.311

8.  Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.

Authors:  Ching-Wei Tsai; Han-Chun Huang; Hsiu-Yin Chiang; Chih-Wei Chung; Shih-Ni Chang; Pei-Lun Chu; Chin-Chi Kuo
Journal:  J Lipid Res       Date:  2019-01-14       Impact factor: 5.922

9.  Disorders of lipid metabolism and chronic kidney disease in the elderly.

Authors:  Devasmita Choudhury; Meryem Tuncel; Moshe Levi
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

10.  Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.

Authors:  Bruce K Birmingham; Suzanne K Swan; Tom Puchalski; Pat Mitchell; Connie Azumaya; Julie Zalikowski; Yi Wang
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.